2-甲基-1,3-噻唑-5-甲酰肼 | 409316-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基-1,3-噻唑-5-甲酰肼
• 英文名称: 2-methyl-thiazole-4-carboxylic acid hydrazide
• 英文别名: 2-methylthiazole-5-carbohydrazide；2-methyl-thiazole-5-carboxylic acid hydrazide；2-Methyl-thiazol-5-carbonsaeure-hydrazid；2-methyl-1,3-thiazole-5-carbohydrazide
• CAS: 409316-66-1
• 化学式: C₅H₇N₃OS
• 分子量: 157.196
• InChiKey: ASGDXBJEPCKVFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-甲基-1,3-噻唑-5-甲酰肼 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 2-(2-(bromomethyl)thiazol-5-yl)-5-(trifluoromethyl)-1,3,4-oxadiazole
  参考文献：
  名称：

  [EN] FLUOROALKYL-OXADIAZOLES AND USES THEREOF
  [FR] OXADIAZOLES FLUOROALKYLÉS ET LEURS UTILISATIONS

  摘要：

  本文提供了被识别为HDAC6活性抑制剂的化合物，可用于治疗各种疾病和疾患。

  公开号：

  WO2021127643A1
• 作为产物：
  描述：

  2-甲基噻唑-5-羧酸乙酯 在 甲醇 、 一水合肼 作用下， 生成 2-甲基-1,3-噻唑-5-甲酰肼
  参考文献：
  名称：

  有关硝噻唑化合物的知识III

  摘要：

  合成了2-硝基-5-溴噻唑，并将该体的性质和响应与异构体2-溴5-硝基噻唑进行了比较。此外，制备2-甲基-5-硝基噻唑，另一方面，通过降解2-甲基-噻唑-5-羧酸获得2-甲基-5-乙酰基氨基噻唑。

  DOI：

  10.1002/hlca.19500330214

文献信息

• Comparison of affinity ranking by target-directed dynamic combinatorial chemistry and surface plasmon resonance
  作者：Priska Frei、Marleen Silbermann、Tobias Mühlethaler、Xiaohua Jiang、Oliver Schwardt、Rachel Hevey、Beat Ernst

  DOI：10.24820/ark.5550190.p010.913

  日期：——

  Target-directed dynamic combinatorial chemistry (tdDCC) is a powerful method to screen ligands for pharmacologically relevant targets. Generating a dynamic library from reversibly reacting building blocks in the presence of a target protein leads to the amplification of the most potent library constituents. In previous studies on tdDCC, these compounds were identified in a qualitative “hit/no-hit”-manner

  靶向动态组合化学 (tdDCC) 是一种有效的方法来筛选药理学相关靶标的配体。在目标蛋白存在的情况下，通过可逆反应构建块生成动态库会导致最有效的库成分放大。在之前对 tdDCC 的研究中，这些化合物以定性的“命中/未命中”方式被鉴定。然而，扩增程度与文库成分亲和力之间的精确关系尚未得到评估。为了研究扩增-亲和力关系，我们比较了 tdDCC 实验，采用可逆酰腙形成和细菌粘附素 FimH 作为靶标，通过表面等离子体共振确定文库成分的亲和力。
• 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：——

  公开号：US20030045581A1

  公开（公告）日：2003-03-06

  The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: 1 wherein A 1 , A 2 , Q and R 1 -R 3 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及可选取代的4-取代-1-(芳基甲基亚胺基)硫脲、4-取代-1-(芳基羰基)硫脲及其类似物，由式I和II表示：其中A1，A2，Q和R1-R3在此定义。本发明还涉及发现具有式I和II的化合物是caspase激活剂和凋亡诱导剂的发现。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在出现异常细胞的无控制生长和扩散的各种临床情况中的细胞死亡。
• 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
  申请人：Bonanomi Giorgio

  公开号：US20090124629A1

  公开（公告）日：2009-05-14

  The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 5 ; each R 2 is independently hydrogen, fluorine or C 1-4 alkyl; n is 2, 3, 4, or 5; R 3 is C 1-4 alkyl; R 4 is hydrogen, or a C 1-4 alkyl group, a benzyl group, a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ;or R 4 is a —SR 6 group; R 5 is selected from a group consisting of: isoxazolyl, —CH 2 —N-pyrrolyl, 1,1-dioxido- 2-isothiazolidinyl, thienyl, thiazolyl, pyridyl and 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from a group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; R 6 is C 1-4 alkyl or —CH 2 C 3-4 cycloalkyl; and when R 1 is chlorine and p is 1, such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1. processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

  本发明涉及以下式（I）的新化合物或其药学上可接受的盐：其中G选自以下组：苯基，吡啶基，苯并噻唑基和吲唑基；p为0至5的整数；R1独立选自以下组：卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4酰基和SF5；或对应于R5基团；每个R2独立地为氢，氟或C1-4烷基；n为2、3、4或5；R3为C1-4烷基；R4为氢，或C1-4烷基，苄基，苯基，杂环基，5-或6-成员杂芳基，或8-至11-成员双环基团，其中任何一个基团可以选择地由1、2、3或4个来自以下组的取代基取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4酰基和SF5；或R4为-SR6基团；R5选自以下组：异噁唑基，-CH2-N-吡咯基，1,1-二氧化-2-异噻唑烷基，噻唑基，吡啶基和2-吡咯烷基，并且此类基团可以选择地由1或2个来自以下组的取代基取代：卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基和C1-4酰基；R6为C1-4烷基或- C3-4环烷基；当R1为氯且p为1时，此类R1不在与分子的其余部分的连接键的正交位置上存在；当R1对应于R5时，p为1。本发明还涉及制备这些化合物的方法，用于这些方法的中间体，包含它们的药物组合物以及它们作为多巴胺D3受体调节剂的用途，例如用于治疗药物依赖，作为抗精神病药物，用于治疗强迫症谱系障碍，早泄或认知障碍。
• 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US06794400B2

  公开（公告）日：2004-09-21

  The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: wherein A1, A2, Q and R1-R3 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及可选取代的4-取代-1-(芳基甲基亚硫基)脲、4-取代-1-(芳基羰基)亚硫基脲及其类似物，其化学式分别为I和II：其中A1、A2、Q和R1-R3在此定义。本发明还涉及发现具有化学式I和II的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于在各种临床情况下诱导细胞死亡，其中出现了异常细胞的不受控制的生长和扩散。
• 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors
  申请人：Glaxo Group Limted

  公开号：US07947683B2

  公开（公告）日：2011-05-24

  The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

  本发明涉及化合物的新型公式（I）或其药学上可接受的盐：制备它们的过程，用于这些过程的中间体，包含它们的制药组合物以及它们作为多巴胺D3受体调节剂的治疗用途，例如治疗药物依赖，作为抗精神病药物，治疗强迫症谱系障碍，早泄或认知障碍。